Clinical Trials Logo
  1. Home
  2. Advanced/Metastatic Solid Tumors
  3. NCT05607498

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid Tumors Clinical Trial

Official title:
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Clinical Trial Summary

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

Clinical Trial Description

This is a phase I, multicenter, open label, dose escalation, first in human study, designed to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose for EMB-07 in patient with locally advanced/metastatic solid tumors or relapse/refractory Lymphoma . Pharmacokinetics, pharmacodynamics, immunogenicity and response will also be assessed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05607498
Study type Interventional
Source EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Contact Xiaodong Sun
Phone +8618512158506
Email xdsun@epimab.com
Status Recruiting
Phase Phase 1
Start date March 1, 2023
Completion date March 31, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Active, not recruiting NCT04501276 - A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients Phase 1
Active, not recruiting NCT04182516 - Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Phase 1
Terminated NCT00996255 - Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors Phase 1
Terminated NCT02444793 - A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03526835 - A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05718895 - A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors Phase 1
Completed NCT03833427 - Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) Phase 1
Recruiting NCT04645069 - ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05405595 - ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02665416 - Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors Phase 1
Terminated NCT01092052 - Study of NMS-1116354 in Advanced/Metastatic Solid Tumors Phase 1
Completed NCT05277402 - ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05614258 - Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05394168 - A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors Phase 1